# CREATE Medicines

Source: https://onco.cc/companies/create-medicines/  
OnCo record `create-medicines` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CREATE Medicines, formerly Myeloid Therapeutics, uses messenger RNA in fat particles, given by drip, to teach a patient's own immune cells inside the body to attack cancer, without collecting and engineering cells in a laboratory. Its cancer trials are in liver, stomach and oesophageal cancers and other solid tumours.

## Summary

CREATE Medicines, renamed from Myeloid Therapeutics in 2025, develops in vivo CAR therapies: mRNA lipid nanoparticles that program T cells, NK cells and myeloid cells inside the body to express a chimeric antigen receptor, allowing repeat dosing without lymphodepletion or ex vivo cell manufacture. Its oncology pipeline lists MT-302 (TROP2-directed, myeloid cells; phase 1 NCT05969041 in advanced epithelial tumours, and the investigator-led SPaCE-MT trial at Amsterdam UMC combining it with CAPOX-based first-line treatment in advanced gastro-oesophageal cancer), MT-303 (GPC3-directed, myeloid cells; phase 1 NCT06478693 in hepatocellular carcinoma, including a first-line cohort with atezolizumab and bevacizumab), MT-304 (HER2-directed, NK and myeloid cells; phase 1 NCT07334119) and a programme directed at both HER2 and TROP2 (T, NK and myeloid cells), all shown at clinical stage. It also develops CD19 and CD19 x BCMA in vivo CAR-T programmes for autoimmune disease and an RNA gene-integration system called RetroT. The company says more than 60 patients have been dosed across its in vivo CAR programmes. In 2026 it formed collaborations with Monash University and WestGene Biopharma, adding to one with Acuitas Therapeutics.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: CREATE Medicines, Inc.; Myeloid Therapeutics; Myeloid Therapeutics, Inc.
- HQ: Cambridge, MA
- Type: biotech
- Website: https://createmedicines.com/

## Notes

- Recorded under the current name, CREATE Medicines, because this was a rename rather than an acquisition; ARCH's portfolio and ClinicalTrials.gov still use the name Myeloid Therapeutics. The rename source is the company's PR Newswire release of 28 Oct 2025 ("CREATE Medicines, Inc., formerly Myeloid Therapeutics, Inc."); the month of the rename was not stated in that release.
- Founding year not stated on the pages read; omitted.
- MT-302 already exists in OnCo as drug `mt-302`; the company should be linked from it. MT-302's OnCo trial record is `nct05969041`.
- MT-101 (NCT05138458, CD5-positive T-cell lymphoma, suspended) is not on the current pipeline page and is not described.
- A secondary profile reports a 2026 Series B; no primary source was read, so no funding is entered.
- The HER2 and TROP2 programme has no ClinicalTrials.gov record found by sponsor search.

## Sources

- Official website: https://createmedicines.com/
- Press release: SPaCE-MT trial of MT-302 begins, names company as formerly Myeloid Therapeutics (28 Oct 2025): https://www.biospace.com/press-releases/create-medicines-and-amsterdam-university-medical-center-initiate-first-in-vivo-car-therapy-trial-in-frontline-setting-for-solid-tumors
- Press release: first patient dosed in frontline HCC cohort of MT-303 (9 Dec 2025): https://www.biospace.com/press-releases/create-medicines-doses-first-patient-in-frontline-hcc-trial-evaluating-mt-303-an-in-vivo-car-therapy-in-combination-with-standard-of-care-immunotherapy
- Press release: WestGene collaboration (28 Aug 2026): https://createmedicines.com/news/create-medicines-expands-clinical-in-vivo-car-pipeline-and-lnp-technology-suite-by-forming
- ClinicalTrials.gov NCT06478693 (MT-303): https://clinicaltrials.gov/study/NCT06478693
- ARCH Venture Partners portfolio entry, as Myeloid Therapeutics (archived 16 Oct 2026): https://web.archive.org/web/20261016142320/https://www.archventure.com/portfolio/

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- targets: [Glypican-3](https://onco.cc/targets/gpc3/), [HER2](https://onco.cc/targets/her2/), [TROP2](https://onco.cc/targets/trop2/)
- drugs: [MT-302](https://onco.cc/drugs/mt-302/), [MT-303](https://onco.cc/drugs/mt-303/), [MT-304](https://onco.cc/drugs/mt-304/)
- trials: [A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC](https://onco.cc/trials/nct06478693/), [Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors](https://onco.cc/trials/nct07334119/), [Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors](https://onco.cc/trials/nct05969041/)
- companies: [ARCH Venture Partners](https://onco.cc/companies/arch-venture-partners/)

---
JSON: https://onco.cc/api/v1/entities/create-medicines.json